Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Gastroenterology
Published in: Indian Journal of Gastroenterology 5/2015

01-09-2015 | Review Article

Portal hypertensive gastropathy and gastric antral vascular ectasia

Authors: Hitendra Garg, Subhash Gupta, A C. Anand, S. L. Broor

Published in: Indian Journal of Gastroenterology | Issue 5/2015

Login to get access

Abstract

Portal hypertensive gastropathy (PHG) and gastric antral vascular ectasia (GAVE) are gastric mucosal lesions that mostly present as chronic anemia and rarely cause the acute gastrointestinal hemorrhage. Despite similar clinical manifestations, their pathophysiology and management are entirely different. PHG is seen exclusively in patients with portal hypertension, but GAVE can also be observed in patients with other conditions. Their diagnosis is endoscopic, and although generally each of them has a characteristic endoscopic appearance and distribution, there are cases in which the differential is difficult and must rely on histology. This review focuses on the management of both entities. The mainstay of management of PHG is based on portal-hypotensive pharmacological treatment while GAVE benefits from hormonal therapy, endoscopic Nd:YAG laser, and argon plasma coagulation. More invasive options should be reserved for refractory cases.
Literature
1.
2.
Jabbari M, Cherry R, Lough JO, et al. Gastric antral vascular ectasia: the watermelon stomach. Gastroenterology. 1984;87:1165–70.PubMed
3.
Spina GP, Arcidiacono R, Bosch J, et al. Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, September 19, 1992. J Hepatol. 1994;21:461–7.CrossRefPubMed
4.
Misra SP, Dwivedi M, Misra V. Prevalence and factors influencing hemorrhoids, anorectal varices, and colopathy in patients with portal hypertension. Endoscopy. 1996;28:340–5.CrossRefPubMed
5.
Sarin SK, Misra SP, Singal AK, et al. Evaluation of the incidence and significance of mosaic pattern in patients with cirrhosis, non-cirrhotic portal fibrosis and extrahepatic obstruction. Am J Gastroenterol. 1988;83:1235–9.PubMed
6.
Sarin SK, Shahi HM, Jain M, Jain AK, Issar SK, Murthy NS. The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol. 2000;95:2888–93.CrossRefPubMed
7.
Fontana RJ, Sanyal AJ, Mehta S, et al. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol. 2006;101:983–92.CrossRefPubMed
8.
Merli M, Nicolini G, Angeloni S, Gentili F, Attili AF, Riggio O. The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol. 2004;99:1959–65.CrossRefPubMed
9.
10.
Sarin SK, Sreenivas DV, Lahoti D, et al. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology. 1992;102:994–9.PubMed
11.
Kim MY, Choi H, Baik SK, et al. Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis. Dig Dis Sci. 2010;55:3561–7.CrossRefPubMed
12.
Kumar A, Mishra SR, Sharma P, Sharma BC, Sarin SK. Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy: a study of 254 cirrhotics. J Clin Gastroenterol. 2010;44:294–300.CrossRefPubMed
13.
De la Pena J, Rivero M, Sanchez E, et al. Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. Gastrointest Endosc. 1999;49:417–23.CrossRefPubMed
14.
Iwao T, Toyonaga A, Oho K, et al. Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. J Hepatol. 1997;26:1235–41.CrossRefPubMed
15.
Bayraktar Y, Balkanci F, Uzunalimoglu B, et al. Is portal hypertension due to liver cirrhosis a major factor in the development of portal hypertensive gastropathy? Am J Gastroenterol. 1996;91:554–8.PubMed
16.
Sarfeh IJ, Tarnawski A. Gastric mucosal vasculopathy in portal hypertension. Gastroenterology. 1987;93:1129–31.PubMed
17.
Payen JL, Cales P, Voigt JJ, et al. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology. 1995;108:138–44.CrossRefPubMed
18.
Beck PL, Lee SS, McKnight W, Wallace JL. Characterization of spontaneous and ethanol-induced gastric damage in cirrhotic rats. Gastroenterology. 1992;103:1048–55.PubMed
19.
Sarfeh IJ, Soliman H, Waxman K, et al. Impaired oxygen of gastric mucosa in portal hypertension. The basis for increased susceptibility to injury. Dig Dis Sci. 1989;34:225–8.CrossRefPubMed
20.
Ferraz JG, Wallace JL. Underlying mechanisms of portal hypertensive gastropathy. J Clin Gastroenterol. 1997;25 Suppl 1:S73–8.CrossRefPubMed
21.
De Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33:846–52.CrossRefPubMed
22.
D’Amico G, Montalbano L, Traina M, et al. Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital. Gastroenterology. 1990;99:1558–64.
23.
Primignani M, Carpinelli L. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC), et al. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. Gastroenterology. 2000;119:181–7.CrossRefPubMed
24.
Lo GH, Cheng JS, Hsu PI, et al. The effects of endoscopic variceal ligation and propanolol on portal hypertensive gastropathy: a prospective controlled trial. Gastrointest Endosc. 2001;53:579–84.CrossRefPubMed
25.
Perez-Ayuso R, Pique J, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 1991;337:1431–4.CrossRefPubMed
26.
Gostout C, Viggiano T, Balm R. Acute gastrointestinal bleeding from portal hypertensive gastropathy: prevalence and clinical features. Am J Gastroenterol. 1993;88:2030–3.PubMed
27.
Hosking S, Kennedy H, Seddon I, Triger D. The role of propanolol in congestive gastropathy of portal hypertension. Hepatology. 1987;7:437–41.CrossRefPubMed
28.
Kouroumalis EA, Koutroubakis IE, Manousos ON. Somatostatin for acute severe bleeding from portal hypertensive gastropathy. Eur J Gastroenterol Hepatol. 1998;10:509–12.CrossRefPubMed
29.
Zhou Y, Qiao L, Wu J, et al. Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. J Gastroenterol Hepatol. 2002;17:973–9.CrossRefPubMed
30.
Bruha R, Marecek Z, Spicak J, et al. Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology. 2002;49:1161–6.PubMed
31.
Ripoll C, Garcia-Tsao G. Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension. Curr Treat Options Gastroenterol. 2007;10:483–94.CrossRefPubMed
32.
de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167–76.CrossRefPubMed
33.
Orloff MJ, Orloff MS, Orloff SL, Haynes KS. Treatment of bleeding from portal hypertensive gastropathy by portacaval shunt. Hepatology. 1995;21:1011–7.PubMed
34.
Hosking SW. Congestive gastropathy in portal hypertension: variations in prevalence. Hepatology. 1989;10:257–8.CrossRefPubMed
35.
Wagatsuma Y, Naritaka Y, Shimakawa T, et al. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology. 2006;53:171–4.PubMed
36.
Karajeh MA, Hurlstone DP, Stephenson TJ, Ray-Chaudhuri D, Gleeson DC. Refractory bleeding from portal hypertensive gastropathy: a further novel role for thalidomide therapy? Eur J Gastroenterol Hepatol. 2006;18:545–8.CrossRefPubMed
37.
Cremers MI, Oliveira AP, Alves AL, Freitas J. Portal hypertensive gastropathy: treatment with corticosteroids. Endoscopy. 2002;34:177.CrossRefPubMed
38.
Mezawa S, Homma H, Ohta H, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol. 2001;96:1155–9.CrossRefPubMed
39.
Sarin SK. Diagnostic issues: portal hypertensive gastropathy and gastric varices. In: DeFranchis R, ed. Portal Hypertension II. Proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford, UK: Blackwell Science; 1996. p. 30–55.
40.
Bourke MJ, Hope RL, Boyd P, et al. Endoscopic laser therapy for watermelon stomach. J Gastroenterol Hepatol. 1996;11:832–4.CrossRefPubMed
41.
Tobin RW, Hackman RC, Kimmey MB, et al. Bleeding from gastric antral vascular ectasia in marrow transplant patients. Gastrointest Endosc. 1996;44:223–9.CrossRefPubMed
42.
Ward EM, Raimondo M, Rosser BG, et al. Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation. J Clin Gastroenterol. 2004;38:898–900.CrossRefPubMed
43.
Spahr L, Villeneuve JP, Dufresne MP, et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut. 1999;44:739–42.PubMedCentralCrossRefPubMed
44.
Charneau J, Petit R, Cales P, et al. Antral motility in patients with cirrhosis with and without gastric antral vascular ectasia. Gut. 1995;37:488–92.PubMedCentralCrossRefPubMed
45.
Quintero E, Piguie JM, Bombs JA, et al. Gastric antral vascular ectasia causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low levels of pepsinogen 1. Gastroenterology. 1987;93:1054–61.PubMed
46.
Goustout CJ, Viggiano TR, Ahlquist DA, et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol. 1992;15:256–63.CrossRef
47.
Geretz JE, Achem SR. The watermelon stomach; clinical presentation, diagnosis and treatment. Am J Gastroenterol. 1998;93:890–5.CrossRef
48.
Potamino S, Carter CR, Anderson JR. Endoscopic laser treatment of diffuse gastric antral vascular ectasia. Gut. 1994;35:461–3.CrossRef
49.
Dulai GS, Jensen DM, Kovacs TO, et al. Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension. Endoscopy. 2004;36:68–72.CrossRefPubMed
50.
Sebastian S, O’Morain CA, Buckley MJ. Review article: current therapeutic options for gastric antral vascular ectasia. Aliment Pharmacol Ther. 2003;18:157–65.CrossRefPubMed
51.
Jensen DM, Chaves DM, Grund KE. Endoscopic diagnosis and treatment of watermelon stomach. Endoscopy. 2004;36:640–7.CrossRefPubMed
52.
Pavey DA, Craig PI. Endoscopic therapy for upper-GI vascular ectasias. Gastrointest Endosc. 2004;59:233–8.CrossRefPubMed
53.
Sebastian S, McLoughlin R, Qasim A, et al. Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia (watermelon stomach): long-term results. Dig Liver Dis. 2004;36:212–7.CrossRefPubMed
54.
Mathou NG, Lovat LB, Thorpe SM, et al. Nd:YAG laser induces long-term remission in transfusion-dependent patients with watermelon stomach. Laser Med Sci. 2004;18:213–8.CrossRef
55.
Wells CD, Harrison ME, Gurudu SR, et al. Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. Gastrointest Endosc. 2008;68:231–6.CrossRefPubMed
56.
57.
58.
59.
Tsai HH, Smith J, Danesh BJ. Successful control of bleeding from gastric antral vascular ectasia (watermelon stomach) by laser photocoagulation. Gut. 1991;32:93–4.PubMedCentralCrossRefPubMed
60.
Bjorkman DJ, Buchi KN. Endoscopic laser therapy of the watermelon stomach. Lasers Surg Med. 1992;12:478–81.CrossRefPubMed
61.
Lingenfelser T, Mueller M, Marks IN, et al. Endoscopic laser therapy in a case of gastric antral vascular ectasia (watermelon stomach). Z Gastroenterol. 1993;31:322–4.PubMed
62.
Fuccio L, Zagari RM, Serrani M, et al. Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia-related bleeding in patients with liver cirrhosis. Digestion. 2009;79:143–50.CrossRefPubMed
63.
Baudet JS, Salata H, Soler M, et al. Hyperplastic gastric polyps after argon plasma coagulation treatment of gastric antral vascular ectasia (GAVE). Endoscopy. 2007;39 Suppl 1:E320.CrossRefPubMed
64.
Farooq FT, Wong RC, Yang P, Post AB. Gastric outlet obstruction as a complication of argon plasma coagulation for watermelon stomach. Gastrointest Endosc. 2007;65:1090–2.CrossRefPubMed
65.
Wahab PJ, Mulder CJ, den Hartog G, Thies JE. Argon plasma coagulation in flexible gastrointestinal endoscopy; pilot experiences. Endoscopy. 1997;29:176–81.CrossRefPubMed
66.
Petrini JL Jr, Johnston JH. Heat probe treatment for antral vascular ectasia. Gastrointest Endosc. 1989;35:324–8.CrossRefPubMed
67.
Cho S, Zanati S, Yong E, et al. Endoscopic cryotherapy for the management of gastric antral vascular ectasia. Gastrointest Endosc. 2008;68:895–902.
68.
Tran A, Villeneuve JP, Bilodeau M, et al. Treatment of chronic bleeding from gastric antral vascular ectasia (GAVE) with oestrogen–progesterone in cirrhotic patients: an open pilot study. Am J Gastroenterol. 1994;94:2909--11.
69.
Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular. Abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther. 1999;13:1429–36.CrossRefPubMed
70.
71.
Suzuki T, Hirano M, Oka H. Long-term corticosteroid therapy for gastric antral vascular ectasia. Am J Gastroenterol. 1996;91:1873–4.PubMed
72.
Dunne KA, Hill J, Dillon JF. Treatment of chronic transfusion-dependent gastric antral vascular ectasia (watermelon stomach) with thalidomide. Eur J Gastroenterol Hepatol. 2006;18:455–6.CrossRefPubMed
73.
Cabral JE, Pontes JM, Toste M, et al. Watermelon stomach: treatment with a serotonin antagonist. Am J Gastroenterol. 1991;86:927–8.PubMed
74.
Kishi K, Kinishita Y, Kitajima N, et al. Two cases of gastric antral vascular ectasia—response to medical treatment. Gastroenterol Jpn. 1999;26:757–62.
75.
Mann NS, Rachut E. Gastric antral vascular ectasia causing severe hypoalbuminemia and anemia cured by antrectomy. J Clin Gastroenterol. 2002;34:284–6.CrossRefPubMed
76.
Vincent C, Pomier-Layrargues G, Dagenais M, et al. Cure of gastric antral vascular ectasia by liver transplantation despite persistent portal hypertension: a clue for pathogenesis. Liver Transpl. 2002;8:717–20.CrossRefPubMed
77.
Ruhl GH, Schnabel R, Peiseler M, et al. Gastric antral vascular ectasia: a case report of a 10 years follow-up with special consideration of histopathological aspects. Z Gastroenterol. 1994;32:160–4.PubMed
Metadata
Title
Portal hypertensive gastropathy and gastric antral vascular ectasia
Authors
Hitendra Garg
Subhash Gupta
A C. Anand
S. L. Broor
Publication date
01-09-2015
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 5/2015
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-015-0605-0

Other articles of this Issue 5/2015

Indian Journal of Gastroenterology 5/2015 Go to the issue

Original Article

The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy

Original Article

Extraintestinal manifestations in inflammatory bowel disease: Prevalence and predictors in Indian patients

Letter

Short sleep duration of overweight and obese patients with erosive esophagitis and gastritis

Short Report

Differences in intestinal metaplasia in Barrett’s esophagus patients in an ethnically diverse south London population

Letter

Low signal-to-cutoff ratio (S/Co) in the diagnosis of hepatitis C: A diagnostic dilemma?

Letter

Kayser-Fleischer rings or bile pigment rings?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits